Results 61 to 70 of about 3,371 (214)
Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials
British Journal of Pharmacology, Volume 183, Issue 7, Page 1364-1389, April 2026.Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen +2 more
wiley +1 more source
Drug Design, Development and Therapy, 2016 Tadakatsu Nakamura,1 Tomoko Kubota,1 Atsushi Iwakaji,1 Masayoshi Imada,1 Margit Kapás,2 Yasunori Morio1 1Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan; 2Developmental Drug Metabolism and ...
Nakamura T +5 more
doaj
Neuropsychiatric Disease and Treatment, 2021 Ágota Barabássy,1 Barbara Sebe,1 Károly Acsai,1 István Laszlovszky,1 Balázs Szatmári,1 Willie R Earley,2 György Németh1 1Medical Division, Gedeon Richter Plc, Budapest, Hungary; 2Clinical Development,
Barabássy Á +6 more
doaj
A Systematic Review of the Effects of Antipsychotics on Anhedonia by Using Knowledge Graph Approach [PDF]
, 2023 Objective: The purpose of the current study is to provides a systematic analysis of the impact of antipsychotic drugs on anhedonia. Methods: We employed the SNOMED CT (Systematized Nomenclature of Medicine - Clinical Terms) and the knowledge graph of ...
Cheng, Xiaoyan +5 more
core +1 more source
International Journal of Mental Health Nursing, Volume 35, Issue 2, April 2026.ABSTRACT The game changers in mental health and substance use disorder treatment have been shaped by historical sea changes marked by transformative advancements that have significantly enhanced patient care. Breakthroughs in psychotherapy, psychosurgery and psychopharmacology have each contributed to reshaping clinical practices, especially the ...
Arlene Kent‐Wilkinson +2 more
wiley +1 more source
Drug Design, Development and Therapy, 2019 Béla Kiss, Zsolt Némethy, Károly Fazekas, Dalma Kurkó, István Gyertyán, Katalin Sághy, István Laszlovszky, Bence Farkas, Norbert Kirschner, Etelka Bolf-Terjéki, Ottilia Balázs, Bal ...
Kiss B +11 more
doaj
BMC Psychiatry, 2021 Background While clinical trial evidence has firmly established the efficacy of several atypical antipsychotics (AAPs) for treating bipolar depression, no randomized controlled trials (RCT’s) comparing AAPs have been conducted. This Bayesian network meta-
Aditi Kadakia +7 more
doaj +1 more source
Case Reports in Psychiatry, Volume 2026, Issue 1, 2026.Background Clozapine‐associated myocarditis (CAM) is the most common inflammatory adverse effect under clozapine treatment. In the absence of equally effective therapeutic alternatives for treating treatment‐resistant schizophrenia (TRS), clinicians are often faced with the question of whether to rechallenge clozapine in patients who have experienced ...
Lukas Zabel +6 more
wiley +1 more source
Cariprazine in offender patient with acute psychosis and aggressive behavior: Case report [PDF]
, 2022 Background Cariprazine, a D3 preferring D3/D2 partial dopamine agonist, has shown to be effective in the treatment of acute psychosis as well as other symptom domains in schizophrenia spectrum disorders.
Kirchebner, Johannes +2 more
core +1 more source
Neuropsychopharmacology Reports, Volume 45, Issue 4, December 2025.Blonanserin transdermal patch may be effective for organic psychosis associated with brain metastasis. Because it can be used in cases where oral medication is difficult and has relatively few side effects, such as hypotension and extrapyramidal symptoms, it may be a helpful option for oncologists and liaison psychiatrists.
Junji Yamaguchi +6 more
wiley +1 more source